Why Novavax (NVAX) is a Top Momentum Stock for the Long-Term

分组1 - Zacks Premium offers various tools for investors to enhance their stock market strategies, including daily updates and access to research reports [1][2] - The Zacks Style Scores categorize stocks into Value, Growth, Momentum, and VGM Scores, helping investors identify stocks with the potential to outperform the market [2][3][6] 分组2 - The Value Score identifies attractive stocks based on valuation ratios like P/E and Price/Sales, appealing to value investors [3] - The Growth Score focuses on a company's future prospects by analyzing earnings, sales, and cash flow, targeting growth investors [4] - The Momentum Score helps investors capitalize on price trends, using metrics like weekly price changes and monthly earnings estimate changes [5] 分组3 - The Zacks Rank is a proprietary model that uses earnings estimate revisions to assist in stock selection, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988 [7][8] - Investors are encouraged to consider stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal investment success [10][11] 分组4 - Novavax, Inc. is a biotechnology company focused on developing vaccines for infectious diseases, currently holding a Zacks Rank of 3 (Hold) and a VGM Score of B [12] - The company has seen a 22.7% increase in share price over the past four weeks, with positive earnings estimate revisions for fiscal 2025 [13]